Sign in
Taking people in United StatesNo phase

Remote Tests for Nerve Problems in Leukemia and Lymphoma Survivors

Compares remote heart rate and symptom tools with in-person tests for nerve problems in survivors.

Key facts

Who runs it
St. Jude Children's Research Hospital
Where
Memphis, United StatesSee the site
Trial code
Registry title
Assessment of Remote Approaches for Identification of Autonomic Dysfunction Among Survivors of Leukemia and Lymphoma
Status
Recruiting
People taking part
188 people, planned
Started
3 Feb 2025
Expected to end
Jun 2027
Type of study
Interventional, 2 groups
Treatments tested
  • Exercise Intervention - Ewing Battery Assessment
  • Questionnaire Administration
  • Medical Device Usage and Evaluation
Record updated
16 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adult survivors of leukemia or lymphoma who are in the St. Jude Lifetime Cohort. It tests if nerve problems of the heart can be found remotely.

Age
Over 18 years
Sex
All sexes can join.
Disease stage
Survivors whose main diagnosis was acute lymphoblastic leukemia (ALL), Hodgkin's Lymphoma (HL), or Non-Hodgkin's Lymphoma (Non-HL).
Earlier treatment
Must not currently be taking beta-blocker medication.

Main reasons for not taking part

  • Cannot speak, read or understand English
  • Cannot follow directions to complete the Ewing battery
  • Acute heart failure
  • Currently pregnant

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Participants enrolled in St. Jude Lifetime Cohort (SJLIFE) >18 years of age
  • Primary diagnosis of acute lymphoblastic leukemia (ALL), Hodgkin's Lymphoma (HL), or Non-Hodgkin's Lymphoma (Non-HL)
  • Not currently taking beta-blocker medication

Who cannot take part

  • Individuals with acute heart failure (new or worsening signs and symptoms of heart failure, including a combination of the following: dyspnea, orthopnea, lower limb swelling, elevated jugular venous pressure, and pulmonary congestion)
  • Individuals who cannot speak, read, and/or understand English
  • Individuals who are unable to follow directions/instructions in order to complete the Ewing battery
  • Women who are currently pregnant

Where in United States

  • St. Jude Children's Research HospitalMemphis, United StatesContact: Kirsten K Ness, PhDTaking people

About the trial

What the trial wants to find out

This study seeks to determine if diagnosing cardiac autonomic dysfunction (AD) can be done remotely with the same accuracy as in-person testing. If so, the identification of AD could happen sooner, facilitating remote studies of the condition and potentially reducing the risk of illness. Childhood cancer survivors, particularly survivors of acute lymphoblastic leukemia (ALL) and Hodgkins's lymphoma (HL), appear to be at increased risk for AD.

Read full original descriptionShow less

Primary Objectives:

* To determine the sensitivity and specificity of heart rate variability (HRV), measured remotely with biosensor technology (Actigraph LEAP), compared to in-person assessment using the Ewing battery as the reference standard to identify cardiac autonomic dysfunction (AD) among survivors of leukemia and lymphoma. * To determine the sensitivity and specificity of the Composite Autonomic Symptom Scale 31 (COMPASS31) compared to the Ewing battery to identify AD among leukemia and lymphoma survivors.

The 2 groups in the trial

  • Screening (COMPASS31 + battery assessment + heart monitor)Treatment being tested

    Patients complete the COMPASS31 questionnaire and undergo an in-person Ewing battery assessment over 60-90 minutes on study. Patients then wear a biosensensor heart monitor for 7 days to monitor heart rate variability remotely on study.

    Treatment: Exercise Intervention - Ewing Battery Assessment, Questionnaire Administration, and Medical Device Usage and Evaluation

  • Screening (battery assessment + COMPASS31 + heart monitor)Treatment being tested

    Patients undergo an in-person Ewing battery assessment over 60-90 minutes and complete the COMPASS31 questionnaire on study. Patients then wear a biosensensor heart monitor for 7 days to monitor heart rate variability remotely on study.

    Treatment: Exercise Intervention - Ewing Battery Assessment, Questionnaire Administration, and Medical Device Usage and Evaluation

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Assessment of Remote Approaches for Identification of Autonomic Dysfunction Among Survivors of Leukemia and Lymphoma
Plain-language title
Remote Tests for Nerve Problems in Leukemia and Lymphoma SurvivorsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
16 July 2026